Still A COVID-19 Game Changer? UK’s Cautious Launch Of MSD’s Antiviral Lagevrio
Efficacy In Vaccinated Population Unproven
Executive Summary
The oral therapy is likely to be a useful addition to the COVID-19 armamentarium, but hopes of it being a ‘game changer’ now look overly optimistic.
You may also be interested in...
Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.
Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron
While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.
The BioPharma Shares Rising On Omicron Hopes And Fears
Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.